Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain

AIDS

Volumn 14, Issue 6, 2000, Pages 727-732

  Puig, Teresa ^f   Pérez Olmeda, Mayte ^a   Rubio, Amalia ^b   Ruiz, Lidia ^e   Briones, Carlos ^a   Franco, José M ^b   Gómez Cano, María ^a   Stuyver, Lieven ^c   Zamora, Laura ^d   Alvarez, Camilo ^d   Leal, Manolo ^b   Clotet, Bonaventura ^f   Soriano, Vicente ^a   Pedreira, José ^f   Cartón, Antonio Juan ^f   Echevarria, Santiago ^f   Iribarren, José Antonio ^f   Cuesta, Julián ^f   Solá, Julio ^f   Del Pozo, Miguel Angel ^f   Alvarez, Luisa ^f   Rubio, Rafael ^f   Gatel, José ^f   Alcácer, Federico ^f   González Lahoz, Juan ^f   Portilla, Joaquin ^f   Villalonga, Concepción ^f   Moreno, Santiago ^f   Kidelan, José M ^f   Marquez, Manuel ^f   Muǹ, Agustín ^f   more..

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c INNOGENETICS   (Belgium)

^d BRISTOL MYERS SQUIBB   (United States)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f NONE

Author keywords

Antiretroviral failure; HAART; HIV; Mutations; Nucleoside reverse transcriptase inhibitors; Prevalence; Primary resistance; Protease inhibitors

Indexed keywords

INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; CODON; DRUG CHOICE; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SPAIN; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MICROBIAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; SPAIN;

EID: 0034008567     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200004140-00012     Document Type: Article

References (21)

1. 1. Hirsch M, Conway B, D'Aquila R, et al. Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management. JAMA 1998, 279:1984-1991.
2. 2. Rodríguez-Rosado R, Briones C, Soriano V. Introduction of HIV drug resistance testing in clinical practice. AIDS 1999, 13:1007-1014.
3. 3. Clevenbergh P, Durant J, Chaillou S, Dellamonica P. HIV drug resistance and insufficient drug plasma levels as factors determining antiretroviral treatment failure. AIDS Reviews 1999, 1:156-166.
4. 4. Hecht F, Grant R, Petropoulos C, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. N Engl J Med 1998, 339:341.
5. 5. Yerly S, Kaiser L, Race E, et al. Transmission of antiretroviral drug resistant HIV-1 variants. Lancet 1999, 354:729-733.
6. 6. Shafer R, Winters M, Palmer S, Merigan T. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated HIV-1 infected patients. Ann Intern Med 1998, 128:906-911.
7. 7. Gómez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naïve and antiretroviral experienced HIV-infected patients in Spain. AIDS 1998, 12:1015-1020.
8. 8. Boom R, Sol C, Salimans M, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990, 28: 495-503.
9. 9. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drug-selected mutations in the HIV type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997, 41:284-291.
10. 10. Schoolmeester A, Nuytten A, Verhelst R, et al. A line probe assay (LiPA) for the detection of drug-selected mutations in the HIV-1 protease gene. Second International Workshop on Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract??].
11. 11. Schmit JC, Ruiz L, Stuyver L, et al. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. J Virol Methods 1998, 73:77-82.
12. 12. Schmit J, Van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue-resistant HIV-1 strains isolated from patients from different European countries. AIDS 1998, 12:2005-2015.
13. 13. Rubio A, Leal M, Pineda JA, et al. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naĩve patients from 1989 to 1996. AIDS 1997, 11:1184-1186.
14. 14. Little S, Daar E, D'Aquila R, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999, 282:1142-1149.
15. 15. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282:1135-1141.
16. 16. Yahi N, Tamalet C, Tourres C, et al. Mutation patterns of the RT and protease genes in HIV-infected patients undergoing combination therapy: survey of 787 sequences. J Clin Microbiol 1999, 37:4099-4106.
17. 17. Ball J, Rowe T, Curran R, et al. Poor reduction of HIV-1 RNA titres in NRTI experienced patients treated with indinavir combination therapy. Sex Trans Infect 1999, 75:337-339.
18. 18. Coakley E, Gillis J, Pedneault L, Dunkle L, Hammer S. Susceptibility of HIV-1 isolates derived from patients treated with didanosine and stavudine in combination. Antiviral Therapy 1997; 2 (suppl 3):95-97.
19. 19. Holguín A, Dietrich U, Immelmann A, et al. Cenotypic and phenotypic resistance to stavudine after long-term monotherapy. Antiviral Ther 1998, 3:183-186.
20. 20. Kavlick M, Wyvill K, Yarchoan R, Mitsuya H. Emergence of multi-dideoxynucleoside-resistant HIV type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J Infect Dis 1998, 177:1506-1513.
21. 21. Briones C, Mas A, Pérez-Olmeda M, et al. Prevalence and genetic heterogeneity of the RT T69SSX insertion in pre-treated HIV-infected patients. AIDS 2000 (in press).